Top 1000 global innovation companies: the second largest R & D expenditure in the medical industry

Source: Biovalley, November 3, 2015 In the 2015 Top 1000 global innovation research, strategy &, a strategic consulting business unit of PWC, analyzed the flow of R & D funds of global enterprises According to the report, since the 2008 annual survey first pointed out the global trend of R & D, enterprises have significantly accelerated the pace of layout innovation around the world The specific performance is that enterprises start to carry out innovation projects overseas in order to obtain top talents and enter the fast-growing market In 2015, the R & D expenditure of the top 1000 global innovation companies reached US $680 billion, an increase of 5.1 percentage points, the largest year-on-year increase since 2012 The R & D expenditure of most industries increased, and the three industries of computer and electronics, medical treatment and automobile ranked in the top three Between 2007 and 2015, the R & D output of automobile enterprises increased by 45%, while that of medical, computer and electronic industries increased by 23% Among them, the R & D expenditure of the computer and electronic industry is the largest, but the decline has been realized In contrast, the R & D expenditure of the medical industry is catching up fast In 2015, the R & D expenditure reached US $145 billion, an increase of 6% In view of the negative growth of the computer and electronics industry, the medical industry is likely to become the industry with the largest R & D expenditure by 2019, the report points out By region, the R & D output of the medical industry is mainly concentrated in the United States and China The United States is the largest R & D input country of the medical industry, with a share of 21% in 2015 China replaced Britain with 14% of the shares, while Japan surpassed Germany and Canada with 9% of the shares By enterprise division, among the top 20 R & D expenditures in 2015, the old multinational pharmaceutical companies Roche, Novartis, Johnson & Johnson, Pfizer, Merck, Sanofi, GlaxoSmithKline and AstraZeneca have been listed, making the medical industry occupy as many as 8 seats As a whole, the R & D intensity (R & D expenditure as a proportion of revenue) of medical enterprises is generally higher than that of other industries This year, AstraZeneca, with 21.4% R & D intensity, surpassed Intel, a software giant.